These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2821720)

  • 21. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma pattern of immunoreactive ACTH in normal man and in patients with Nelson's syndrome.
    Thorén M; Ajne M; Hall K
    Acta Endocrinol (Copenh); 1981 Jan; 96(1):15-23. PubMed ID: 6257016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome.
    Chrousos GP; Schulte HM; Oldfield EH; Gold PW; Cutler GB; Loriaux DL
    N Engl J Med; 1984 Mar; 310(10):622-6. PubMed ID: 6319991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal evaluation of adrenocorticotrophin and beta-lipotrophin plasma levels following bilateral adrenalectomy in patients with Cushing's disease.
    Moreira AC; Castro M; Machado HR
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):91-6. PubMed ID: 8394230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4039-46. PubMed ID: 11095430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticotropin-releasing factor test in normal subjects and patients with hypothalamic-pituitary-adrenal disorders.
    Nakahara M; Shibasaki T; Shizume K; Kiyosawa Y; Odagiri E; Suda T; Yamaguchi H; Tsushima T; Demura H; Maeda T
    J Clin Endocrinol Metab; 1983 Nov; 57(5):963-8. PubMed ID: 6311867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal responses to vasoactive intestinal peptide and corticotropin releasing hormone during the spontaneous remission of Cushing's disease.
    Cannavò S; Li Calzi L; Aragona A; Trimarchi F
    J Endocrinol Invest; 1988 Jun; 11(6):425-8. PubMed ID: 2850311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A patient with recurrent hypercortisolism after removal of an ACTH-secreting pituitary adenoma due to an adrenal macronodule.
    Timmers HJ; van Ginneken EM; Wesseling P; Sweep CG; Hermus AR
    J Endocrinol Invest; 2006 Nov; 29(10):934-9. PubMed ID: 17185905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated levels of adrenocorticotropin (ACTH) precursors in post-adrenalectomy Cushing's disease and their regulation by glucocorticoids.
    Ray DW; Gibson S; Crosby SR; Davies D; Davis JR; White A
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2430-6. PubMed ID: 7629238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of sodium valproate on plasma ACTH and cortisol concentrations in Cushing's disease and Nelson's syndrome.
    Kasperlik-Załuska A; Drac-Kaniewska J; Migdalska B; Jeske W; Wiśniewska-Woźniak T
    Endokrynol Pol; 1988; 39(5):245-52. PubMed ID: 2855625
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and cushing's disease.
    Elias AN; Gwinup G; Valenta LJ
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):151-4. PubMed ID: 6273025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease.
    Reincke M; Allolio B; Kaulen D; Jaursch-Hancke C; Winkelmann W
    Klin Wochenschr; 1988 Aug; 66(15):686-9. PubMed ID: 2845188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).
    Correa-Silva SR; Nascif SO; Molica P; Sá LB; Vieira JG; Lengyel AM
    Clin Endocrinol (Oxf); 2010 Jan; 72(1):70-5. PubMed ID: 19453623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
    Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Silent"corticotropinoma.
    Pawlikowski M; Kunert-Radek J; Radek M
    Neuro Endocrinol Lett; 2008 Jun; 29(3):347-50. PubMed ID: 18580839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
    Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
    J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Responsivity of adrenocorticotropin to corticotropin-releasing hormone and lack of suppressibility by dexamethasone are related phenomena in Cushing's disease.
    Hermus AR; Pieters GF; Pesman GJ; Smals AG; Benraad TJ; Kloppenborg PW
    J Clin Endocrinol Metab; 1986 Apr; 62(4):634-9. PubMed ID: 3005353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary microadenomas causing Cushing's disease respond to corticotropin-releasing factor.
    Orth DN; DeBold CR; DeCherney GS; Jackson RV; Alexander AN; Rivier J; Rivier C; Spiess J; Vale W
    J Clin Endocrinol Metab; 1982 Nov; 55(5):1017-9. PubMed ID: 6288750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome.
    Lamberts SW; Klijn JG; de Quijada M; Timmermans HA; Uitterlinden P; de Jong FH; Birkenhäger JC
    J Clin Endocrinol Metab; 1980 Aug; 51(2):307-11. PubMed ID: 6249835
    [No Abstract]   [Full Text] [Related]  

  • 40. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.
    Ambrosi B; Bochicchio D; Fadin C; Colombo P; Faglia G
    J Endocrinol Invest; 1990 Mar; 13(3):257-61. PubMed ID: 1973178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.